Browsing by Author "Boukichou-Abdelkader, Nisa (57216392995)"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial(2023) ;Gabriel, Rafael (7103316027) ;Boukichou-Abdelkader, Nisa (57216392995) ;Gilis-Januszewska, Aleksandra (7801318789) ;Makrilakis, Konstantinos (6603246389) ;Gómez-Huelgas, Ricardo (7004734060) ;Kamenov, Zdravko (6603678114) ;Paulweber, Bernhard (36519500600) ;Satman, Ilhan (6603732754) ;Djordjevic, Predrag (57200124383) ;Alkandari, Abdullah (56182455000) ;Mitrakou, Asimina (7004179428) ;Lalic, Nebojsa (13702597500) ;Egido, Jesús (35463099300) ;Más-Fontao, Sebastián (6701721229) ;Calvet, Jean Henri (37664688100) ;Pastor, José Carlos (56871286300) ;Lindström, Jaana (55646081100) ;Lind, Marcus (13402929500) ;Acosta, Tania (36518089000) ;Silva, Luis (57216391876)Tuomilehto, Jaakko (36012823000)Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3–33.9) with metformin alone, by 17.3% (95% CI 7.4–27.2) with linagliptin alone, and by 19.5% (95% CI 10.1–29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38–6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy −0.3 mmol/L (95%CI: −0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin −0.2 mmol/L (95% CI: −0.37; −0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by −2.0 kg (95% CI: −5.65; −1.65, p = 0.0006) with metformin monotherapy, and by −1.9 kg (95% CI: −3.02; −0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo. © 2023 by the authors.
